Biogen pulls controversial Alzheimer's drug Aduhelm
Washington (AFP) - A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday. The US Food and Drug Administration awarded accelerated approval to Aduhelm in June 2021, a decision that was highly contentious at the time because the agency overruled its own independent advisors, who found there was insufficient evidence of benefit. At least three of the 11-member independent committee that voted unanimously against recommending the drug...